Kloxxado Spray
Product Images NDC 59467-679

15 FDA label images from Hikma Specialty Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Kloxxado (NDC 59467-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Specialty Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-chemical-structure-usp.jpg (Image Chemical Structure Usp)

Image-chemical-structure-usp.jpg (Image Chemical Structure Usp)
Chemical structure diagram of Naloxone Hydrochloride Dihydrate (Naloxone HCl .2H2O), showing rings, functional groups, and stereochemistry as part of the active ingredient in KLOXXADO nasal spray.*
FDA Label Image

Figure1-plot-a-09.29.2025.jpg (Figure1 Plot A 09.29.2025.jpg)

Figure1-plot-a-09.29.2025.jpg (Figure1 Plot A 09.29.2025.jpg)
A pharmacokinetic line graph titled 'Plot A' depicting mean naloxone concentrations in plasma (ng/mL) over time (hours). The graph compares three nasal spray formulations: KLOXXADO 4 mg, a previously approved naloxone 4 mg nasal spray, and KLOXXADO 8 mg. Concentrations peak early and decline over 4 hours, with KLOXXADO 8 mg showing the highest plasma levels.*
FDA Label Image

Figure1-plot-b-09.29.2025.jpg (Figure1 Plot B 09.29.2025.jpg)

Figure1-plot-b-09.29.2025.jpg (Figure1 Plot B 09.29.2025.jpg)
A line graph labeled Plot B showing mean naloxone concentrations in plasma (ng/mL) over time (hours) for three nasal spray formulations: KLOXXADO 4 mg, a previously approved Naloxone 4 mg nasal spray, and KLOXXADO 8 mg. The graph includes error bars and indicates that the 8 mg KLOXXADO nasal spray reaches higher plasma concentrations over 0.5 hours compared to the other formulations.*
FDA Label Image

Figure-2-plot-a-09.29.2025.jpg (Figure 2 Plot A 09.29.2025.jpg)

Figure-2-plot-a-09.29.2025.jpg (Figure 2 Plot A 09.29.2025.jpg)
A line plot titled 'Plot A' showing Mean Naloxone Concentration in Plasma (ng/mL) on the y-axis versus Time (hr) on the x-axis. The graph compares pharmacokinetic data from two studies for different administration routes and doses of Naloxone: Nasal Spray 8 mg, Intravenous Injection 2 mg, and Intramuscular Injection 0.4 mg, each represented with distinct marker styles and lines. Concentration peaks near time zero and declines over 4 hours.*
FDA Label Image

Figure-2-plot-b-09.29.2025.jpg (Figure 2 Plot B 09.29.2025.jpg)

Figure-2-plot-b-09.29.2025.jpg (Figure 2 Plot B 09.29.2025.jpg)
This plot (Plot B) shows mean naloxone concentration in plasma (ng/ml) over time (hours) comparing different administrations of naloxone: nasal spray 8 mg (Studies I and II), intravenous injection 2 mg (Study II), and intramuscular injection 0.4 mg (Studies I and II). The graph illustrates concentration changes from 0 to 0.5 hours after dosing.*
FDA Label Image

Peeling-back-blister-with-zoom-of-triangle (Image 01)

Peeling-back-blister-with-zoom-of-triangle (Image 01)
An instructional illustration showing hands peeling back a protective seal from a KLOXXADO (naloxone HCl) nasal spray package. A zoomed inset focuses on the product labeling, highlighting the brand name KLOXXADO, the active ingredient naloxone HCl, the strength of 8 mg/0.1 mL, and partial usage instructions indicating nasal route and dosage.*
FDA Label Image

Ifu-image-2-proper-way-to-hold-device (Image 04)

Ifu-image-2-proper-way-to-hold-device (Image 04)
An instructional illustration showing a hand holding a nasal spray device, with labeled parts including the nozzle and plunger. This likely demonstrates the proper way to use the spray.*
FDA Label Image

Ifu-image-3-support-back-of-neck (Image 05)

Ifu-image-3-support-back-of-neck (Image 05)
An instructional black-and-white line drawing showing a person lying down while another person is administering KLOXXADO nasal spray into one nostril, with one hand holding the nasal spray device and the other supporting the patient's head from behind.*
FDA Label Image

Ifu-image-4-insert-tip-into-nostril (Image 06)

Ifu-image-4-insert-tip-into-nostril (Image 06)
An instructional line drawing showing the use of a nasal spray device. The illustration depicts a hand holding the spray applicator, administering a spray into a nostril, indicating the proper technique for nasal spray administration.*
FDA Label Image

Ifu-image-5-place-patient-on-their-side (Image 07)

Ifu-image-5-place-patient-on-their-side (Image 07)
An instructional diagram showing a person lying on their side with one knee bent to prevent rolling onto the stomach and one hand supporting the head. The image includes labels explaining these body positions.*
FDA Label Image

Ifu-image-6-clock-2-3-minutes (Image 08)

Ifu-image-6-clock-2-3-minutes (Image 08)
An illustration of a circular timer depicting a 2-3 minute interval, with a highlighted segment representing the elapsed time. This figure could be used in instructional content related to KLOXXADO nasal spray for naloxone HCL.*
FDA Label Image

Kloxxado-8mg-fc-c50001063-03-k01 (Image 09)

Kloxxado-8mg-fc-c50001063-03-k01 (Image 09)
Packaging label for KLOXXADO (naloxone HCl) nasal spray 8 mg by Hikma Specialty USA Inc. The label includes usage instructions for opioid overdose, a two-pack box indication, and warnings such as not testing the device before use. The packaging is predominantly white with orange and green text, including barcodes and product NDC 59467-679.*
FDA Label Image

Kloxxado-8mg-foil-peel-backing-c50001064-02-k01 (Image 10)

Kloxxado-8mg-foil-peel-backing-c50001064-02-k01 (Image 10)
KLOXXADO nasal spray 8 mg label for naloxone HCL by Hikma Specialty USA Inc. The label specifies the dosage form as nasal spray, intended for nasal use with one spray per unit. It includes storage instructions and cautions, and prominently states it is for known or suspected opioid overdose. The label features the product NDC 59467-679-01 and the Hikma logo.*
FDA Label Image

Kloxxado-8mg-device-label-front-c50001068-01-k01 (Image 11)

Kloxxado-8mg-device-label-front-c50001068-01-k01 (Image 11)
KLOXXADO (naloxone HCL) nasal spray 8 mg label featuring an orange background and white text. The label includes the product name, strength, and route of administration along with the NDC number 59467-679-01, and usage instructions indicating use in the nose only. The labeler is Hikma Specialty USA Inc.*
FDA Label Image

Kloxxado-8mg-device-label-back-c50001067-01-k01 (Image 12)

Kloxxado-8mg-device-label-back-c50001067-01-k01 (Image 12)
Packaging label for KLOXXADO nasal spray containing 8 mg/0.1 mL of Naloxone HCL. The label shows a predominantly orange background with the Hikma Specialty USA Inc. logo in white on the left side and a barcode at the top center. The label design is curved to fit the spray device.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.